

## IPR

<b>Calendar Year</b>	<b>2015</b>	<b>2014</b>	<b>2013</b>
No. of Patents Filed	0	0	0
No. of Patents Published	0	0	0
No. of Patents Granted	0	0	0
No. of Patents Licensed	0	0	0

**Did your institution transfer atleast one technology in the previous three years?**

**Yes**

**No** ✓

<b>Calendar Year</b>	<b>2015</b>	<b>2014</b>	<b>2013</b>
Earning From Patents (Amount in Rupees)	<b>0</b>	<b>0</b>	<b>0</b>
Enter Amount in Words	<b>0</b>	<b>0</b>	<b>0</b>

## Sponsored Research Details

### Sponsored Research Details

#### Prescribed format

Sponsored Research Projects								
S.No.	Financial Year	Name of Faculty (Principal Investigator)	Name of the Funding agency	Title of the Project	Sanctioned order no.	Sanctioned date	Amount Received (In Rupees)	Amount received (in words)
1	2015-16	1. Dr. Jayaraj G. Gudi	ICMR	Estimation of ischemia modified albumin in acute stroke with and without diabetes mellitus : a one year cross sectional study	No. 3/2/May.2015/PG-Thesis-HRD(7)	06/05/2015	25,000/-	Twenty five thousand
		2. Dr. Harpreet Kour	ICMR	Evaluation of the effect of structured exercise therapy on neuro physiological and cognitive functions of young adults with type-2 diabetes mellitus		27/03/2015	25,000/-	Twenty five thousand
		3. Dr B S Kodkany	The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA	Maternal and Newborn Health Registry (MNH Registry)	1U10HD076457-01	06-05-2013	2,66,40,976/-	Two crore sixty six lakh forty thousand nine hundred and seventy six
		4. Dr B S Kodkany	Bill & Melinda Gates Foundation, USA	Better Birth Trial WHO Safe Childbirth Checklist Programm at UttarPradesh	OPP1017378	2012	57,29,901/-	Fifty seven lakh twenty nine thousand nine hundred and one

S.No.	Financial Year	Name of Faculty (Principal Investigator)	Name of the Funding agency	Title of the Project	Sanctioned order no.	Sanctioned date	Amount Received (In Rupees)	Amount received (in words)
		5. Dr B S Kodkany  Dr. Shridevi Metgud  Dr. Pramila Koli	1. The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA 2. Bill & Melinda Gates Foundation, USA	Preconception Maternal Nutrition: A randomized trial of the Global Network for Women's and Children's Health Research in Collaboration with the Bill and Melinda Gates Foundation"	OPP1055867	20-12-2012	2,58,59,618/-	Two crore fifty eight lakhs fifty nine thousand six hundred and eighteen
		6. Dr B S Kodkany  Dr M C Metgud	The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA	Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)	1U10HD076457	2015	75,19,209/-	Seventy five lakh nineteen thousand two hundred and nine
		7.  Dr M B Bellad	University of British Columbia, Canada  Bill and Melinda Gates Foundation, USA	The CLIP (Community Level Interventions for Pre-Eclampsia) Cluster Randomized Trial	F13-03649	Sep 21, 2013	6,46,82,256/-	Six crore forty six lakh eighty two thousand two hundred and fifty six

S.No.	Financial Year	Name of Faculty (Principal Investigator)	Name of the Funding agency	Title of the Project	Sanctioned order no.	Sanctioned date	Amount Received (In Rupees)	Amount received (in words)
		8. Dr M B Bellad	Thrasher Research Fund, USA	Clindamycin to Reduce Preterm Birth in a Low Resource Setting: A Randomized Placebo-Controlled Trial	601465	June 22, 2013	57,23,461/-	Fifty seven lakh twenty three thousand four hundred and sixty one
		9. Dr. Sangamma	ICMR	Estimation of fructosamine & glycated Hb in newly diagnosed Subclinical hypothyroid and hypo & hyper thyroid patients without diabetes mellitus - A one year cross sectional study	No.3/2/March 2016 /PG Thesis HRD (4) Dated 29.03.2016	29-03-2016	15,000/-	Fifteen thousand
		10. Mr. Priyanshu Jain	ICMR	Prevalence of Depression & anxiety among urban diagnose Diabetic Patients	Ref:21/1/2015/B MS-STs	STS 2015	10,000/-	Ten thousand
		11. Dr. Mahantesh M Nagamoti	National cancer Institution USA & ICMR	Improving cervical cancer prevention among HIV infected women using novel HPV based biomarkers assay- An "intramural to India" study (HIV-HPV project)	ICMR Ref No : Indo-Us/104/9/2010-ECD-II0	2014-15	10,50,000/-	Ten lakh and fifty thousand
		12. Dr. Mahantesh Nagamoti	KSAPS, Bangalore	HIV Sentinel Surveillance - ongoing	KSAPS/DD (M&E) / HSS /04/2012-13	11.01.2013	12,000/-	Twelve thousand
		13. Dr. Mahantesh MNagamoti	KSAPS, Bangalore	External Quality Assurance Scheme for HIV Testing – SRL- ongoing	KSAPS/BSP/EQ UAS/10/ 2013-14	8.07.2013	15,000/-	Fifteen thousand

S.No.	Financial Year	Name of Faculty (Principal Investigator)	Name of the Funding agency	Title of the Project	Sanctioned order no.	Sanctioned date	Amount Received (In Rupees)	Amount received (in words)
		14. Dr. Ganga Pilli	DHR-ICMR	Training Programme in the area of Good Laboratory Practices	V-25011/25 (5)/2013- HR	26/9/2014	9,80,000/-	Nine lakh and eighty thousand
		15. Dr. Shivprasad S Goudar	DBT-MRC-DFID,UK	“Evaluation of the introduction of a novel device in the management of hypertension and shock in pregnancy in low –resource setting	Ref No: MDC /IECHSR/2015-16/A-59	26 <sup>th</sup> August 2015	1,72,58,000/-	One crore seventy two lakh and fifty eight thousand
		16. Dr. (Mrs) N S Mahantashetti	GlaxoSmithKline	A seamless, sequential Phase III, randomized, multi center single blind study to evaluate immunogenicity, safety, reactogenicity of liquid ROTAVAC 5C formulation of the live attenuated vaccine as a 3-dose series when compared with existing ROTAVC® in healthy infants.		08.04.2015 to 18.09.2015	8,70,000/-	Eight lakh and seventy thousand
		17.Dr. Yogesh Kumar S.	Govt. of Karnataka, Directorate of Health & Family Welfare Services, Bengaluru	Iodine Deficiency Disorders (IDD) Re-Survey in 6-12 yrs children of Belagavi District	Ref:NPG/IDD/18 /2014-15	6 <sup>th</sup> December 2014	50,000/-	Fifty thousand
		18.Dr. Shivanand C. Mastiholi	ICMR	Nutritional status of preconception women in rural areas of Belgaum District - A Cross Sectional Study	Ref:3/2/2014/PG-thesis-HRD-25	18 <sup>th</sup> March 2014	25,000/-	Twenty five thousand

S.No.	Financial Year	Name of Faculty (Principal Investigator)	Name of the Funding agency	Title of the Project	Sanctioned order no.	Sanctioned date	Amount Received (In Rupees)	Amount received (in words)
		19.Dr.Divyae Kansal	Karnataka Chapter (RSSDI)	Prevalence of Gestational Diabetes Mellitus among Pregnant women attending Antenatal Clinics at three Urban Health Centres of Belgaum – A Cross Sectional Study	---	25 <sup>th</sup> June 2015	20,000/-	Twenty thousand
		20. Dr. B.S. Kodkany 21. Dr. S.S. Goudar, 22. Dr. N.S. Mahantshetti 23. Dr. M.B. Bellad 24. Dr. R.M. Bellad 25. Dr. S.M. Dhaded 26. Dr. Yeshita Pujar 27. Dr. Hema Dhumale 28. Dr. M.C. Metgud  Dept. of	<ul style="list-style-type: none"> <li>• NIH, USA</li> <li>• NICHD, USA</li> <li>• Global Implementation Task Force of American Academy of Pediatrics, USA</li> <li>• Bill and Melinda Gate's Foundation, USA</li> <li>• WHO,</li> <li>• Thrasher Research Fund, USA</li> </ul>	21. Research on Women and child Health 22. Maternal and Newborn Health Registry (MNH Registry)Dept. of OBG & Paediatrics 23. Helping babies breathe initiative Dept. of Paediatrics 24. The CLIP (Community Level Interventions for Pre-Eclampsia) Cluster randomized controlled trial Dept. of OBG 25. Does Implementation of Helping Babies Breathe (HBB) save lives? Dept. of Paediatrics 26. Antenatal corticosteroids trial in preterm births to increase neonatal survival in	G13-03889,  1U10HD067459	2014	1,61,22,004/-	One crore sixty one lakh twenty two thousand and four

		<p>Paediatrics, ObG, Physiology, Community Medicine of J.N. Medical College, Belagavi</p>	<ul style="list-style-type: none"> <li>• International Atomic Energy Agency, Vienna</li> <li>• RHR Division of World Health Organization, Geneva, Switzerland</li> <li>• University of Colorado Health Sciences Center</li> <li>• The Children Investment Fund Foundation, USA</li> <li>• Research Triangle Institute USA</li> <li>• Engender Health, USA Maternal Health Task Force, USA</li> </ul>	<p>developing countries (ACT) in Belagavi District, Karnataka, India</p> <p>Dept. of OBG &amp; Paediatrics</p> <p>27. Emergency obstetrics and newborn care (EmONC Project) Dept. of Paediatrics &amp; OBG</p> <p>28. Women first: Preconception maternal nutrition: A randomized trial Dept. of OBG</p> <p>29. Brain research to ameliorate impaired neurodevelopment: Home-based intervention trial (BRAIN HIT)</p>				
--	--	---	--	---	--	--	--	--

S.No.	Financial Year	Name of Faculty (Principal Investigator)	Name of the Funding agency	Title of the Project	Sanctioned order no.	Sanctioned date	Amount Received (In Rupees)	Amount received (in words)
2	2014-15	1. Dr B S Kodkany Dr. Shridevi Metgud Dr. Pramila Koli	The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA	Antenatal Corticosteroids Trial in Preterm Births to Increase Neonatal Survival in Developing Countries (ACT)	1U10HD076457-1	06-05-2013	1,36,76,006/-	One crore thirty six lakh seventy six thousand and six
		2. Dr B S Kodkany Dr M C Metgud	1. The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA 2. Norwegian Agency for Development Cooperation (NORAD), Oslo, Norway 3. Laerdal Foundation, Stavanger, Norway	Evaluation of HELPING BABIES BREATHE in Belgaum, Kenya and Nagpur: Does Implementation of HELPING BABIES BREATHE Save Lives?	1U10HD076457-1	06-05-2013	2,32,47,039/-	One crore thirty two lakh forty seven thousand and thirty nine



S.No.	Financial Year	Name of Faculty (Principal Investigator)	Name of the Funding agency	Title of the Project	Sanctioned order no.	Sanctioned date	Amount Received (In Rupees)	Amount received (in words)
		3. Dr B S Kodkany	The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA	Maternal and Newborn Health Registry (MNH Registry)	1U10HD076457-01	06-05-2013	1,47,81,363/-	One crore forty seven lakh eighty one thousand three hundred and sixty three
		4. Dr B S Kodkany	Bill & Melinda Gates Foundation, USA	Better Birth Trial WHO Safe Childbirth Checklist Programme at Uttar Pradesh	OPP1017378	2012	94,14,933/-	Ninety four lakh fourteen thousand nine hundred and thirty three
		5. Dr B S Kodkany	1. The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA 2. Bill & Melinda Gates Foundation, USA	Preconception Maternal Nutrition: A randomized trial of the Global Network for Women's and Children's Health Research in Collaboration with the Bill and Melinda Gates Foundation"	OPP1055867	20-12-2012	1,43,81,218/-	One crore forty three lakh eighty one thousand two hundred and eighteen
		6. Dr M B Bellad	University of British Columbia, Canada Bill and Melinda Gates Foundation, USA	The CLIP (Community Level Interventions for Pre-Eclampsia) Cluster Randomized Trial	F13-03649	Sep 21, 2013	1,39,41,427/-	One crore thirty nine lakh forty one thousand four hundred and twenty seven

S.No.	Financial Year	Name of Faculty (Principal Investigator)	Name of the Funding agency	Title of the Project	Sanctioned order no.	Sanctioned date	Amount Received (In Rupees)	Amount received (in words)
		7. Dr M B Bellad	Thrasher Research Fund, USA	Clindamycin to Reduce Preterm Birth in a Low Resource Setting: A Randomized Placebo-Controlled Trial	601465	June 22, 2013	1,45,99,234/-	One crore forty five lakh ninety nine thousand two hundred and thirty four
		8. Dr S S Goudar Dr. Yeshita Pujar Dr. Namrata Jadhav	Department of Reproductive Health & Research, World Health Organization, Geneva	A phase III, randomized, double- blind, active, controlled, multinational, multicenter, non-inferiority trial using carbetocin room temperature stable (RTS) for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally	2014/432421-0	June 15, 2014	2,78,48,393/-	Two crore seventy eight lakh forty eight thousand three hundred and ninety three
		9. Dept. of Paediatrics	International Atomic Energy Agency, Vienna	Zinc and iron bioavailability from bio-fortified pearl millet Dept. of Paediatrics	15205/RO	01/10/2010	3,60,000/-	Three lakh sixty thousand
		10. Dr.Jayaraj	ICMR	Estimation of ischemia modified albumin in acute stroke with & without diabetes –A one year cross – sectional study	3/2/May 2015 /PG-thesis HRD - 7 Dated 06-05-2015	06-05-2015	15,000/-	Fifteen thousand
		11. Ms.Harini Singara Chari	ICMR	Practice of self medication and polypharmacy among households of urban area – A cross sectional Study	Ref: 2014-00327	STS 2014	10,000/-	Ten thousand

S.No.	Finan cial Year	Name of Faculty (Principal Investigator)	Name of the Funding agency	Title of the Project	Sanctioned order no.	Sanctioned date	Amount Received (In Rupees)	Amount received (in words)
		12. Ms.Soumya	ICMR	Factors associated with treatment default among tuberculosis patients – A case control study	Ref:21/1/2014- BMS-STS	STS 2014	10,000/-	Ten thousand
		13. Ms.Vineela Mikkilineni	ICMR	Assessment of Undernutrition among Children attending Anganwadi by using Anthropometric Indices - A Cross Sectional Study	Ref:2014-04502	STS 2014	10,000/-	Ten thousand
		14. Ms.Ankita Priyadarshini	ICMR	Health Education as a tool to quit tobacco use among non-teaching staff in a medical college of north Karnataka - An interventional study	Ref:21/1/2014- BMS-STS	STS 2014	10,000/-	Ten thousand
		15. Dr. (Mrs) N S Mahantashetti	GlaxoSmithKline	Phase IV, Multicenter, randomized, single-Blind , study to evaluate the immunogenicity, Reactogenicity & safety of the live attenuated rotavirus vaccine ROTVAC <sup>®</sup> as a 3 dose series when administered simultaneously with or without the buffering agent following in healthy infants.		09.10.2014 to 06.12.2014	6,36,000/-	Six lakh thirty six thousand

S.No.	Financial Year	Name of Faculty (Principal Investigator)	Name of the Funding agency	Title of the Project	Sanctioned order no.	Sanctioned date	Amount Received (In Rupees)	Amount received (in words)
		16. Dr. M.K.Swamy	Indian Council of Medical Research, New Delhi	Evaluation of a Progesterone Vaginal Ring a New Contraceptive Option in India	BT/IN/US/02/MR/2010	23 –May 2012	1,09,482/-	One Lakh nine thousand four hundred and eighty two
		17. Dr.Mahantesh Nagamoti	KSAPS, Bangalore	HIV Sentinel Surveillance - ongoing	KSAPS/DD (M&E) / HSS /04/2012-13	11.01.2013	16,000/-	Sixteen thousand
		18. Dr.Mahantesh MNagamoti	KSAPS, Bangalore	External Quality Assurance Scheme for HIV Testing – SRL- ongoing	KSAPS/BSP/EQ UAS/10/ 2013-14	8.07.2013	12,000/-	Twelve Thousand
		19. Dr.Mahantesh Nagamoti	National cancer Institution USA & ICMR	Improving cervical cancer prevention among HIV infected women using novel HPV based biomarkers assay- An "intramural to India" study (HIV-HPV project)	ICMR Ref No : Indo-Us/104/9/2010-ECD-II0	2014-15	10,50,000/-	Ten lakhs fifty thousand
		20. Dr. B.S. Kodkany 21. Dr. S.S. Goudar,	<ul style="list-style-type: none"> <li>Global Implementati on Task Force of</li> </ul>	<ol style="list-style-type: none"> <li>1. Research on Women and child Health</li> <li>2. The CLIP (Community Level Interventions for</li> </ol>	G13-03889, 1U10HD067459	2014	1,38,99,994/-	One crore thirty eight lakh ninety nine

	<p>22. Dr. N.S. Mahantshetti</p> <p>23. Dr. M.B. Bellad</p> <p>24. Dr. R.M. Bellad</p> <p>25. Dr. S.M. Dhaded</p> <p>Dept. of Paediatrics, ObG, Physiology of J.N. Medical College, Belagavi</p>	<p>American Academy of Pediatrics, USA</p> <ul style="list-style-type: none"> <li>• Bill and Melinda Gate's Foundation, USA</li> <li>• WHO, Thrasher Research Fund, USA</li> <li>• International Atomic Energy Agency, Vienna</li> <li>• RHR Division of World Health Organization, Geneva, Switzerland</li> </ul>	<p>Pre- Eclampsia) Cluster randomized controlled trial Dept. of OBG</p> <p>3. Emergency obstetrics and newborn care (EmONC Project) Dept. of Paediatrics &amp; OBG</p> <p>4. Women first: Preconception maternal nutrition: A randomized trial Dept. of OBG</p> <p>5. Active management of the third stage of labour without controlled cord traction: A randomized non-inferiority controlled trial Dept. of OBG</p>				<p>thousand  nine hundred  and ninety  four</p>
--	--	--	---	--	--	--	---

S.No.	Financial Year	Name of Faculty (Principal Investigator)	Name of the Funding agency	Title of the Project	Sanctioned order no.	Sanctioned date	Amount Received (In Rupees)	Amount received (in words)
3	2013-14	1. Dept. of OBG & Paediatrics	National Institute of Child Health and Human Development, National Institutes of Health, USA.	Maternal and Newborn Health Registry (MNH Registry) Dept. of OBG & Paediatrics	5U01HD042372-10 (revised)	2011	4,11,05,000/-	Four crore eleven lakh five thousand
		2. Dept. of Paediatrics	Global Implementation Task Force of American Academy of Pediatrics, USA	Helping babies breathe initiative Dept. of Paediatrics	7U01HD042372-08 (revised)	05/01/2010	1,43,62,000/-	One crore forty three lakh sixty two thousand
		3. Dept. of OBG	RHR Division of World Health Organization, Geneva, Switzerland	Active management of the third stage of labour without controlled cord traction: A randomized non-inferiority controlled trial Dept. of OBG	A65554	20/04/2009	42,04,000/-	Forty two lakhs four thousand
		4. Dr B S Kodkany Dr. Shridevi Metgud Dr. Pramila Koli	The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA	Antenatal Corticosteroids Trial in Preterm Births to Increase Neonatal Survival in Developing Countries (ACT)	1U10HD076457-1	06-05-2013	1,16,95,771/-	One crore sixteen lakh ninety five thousand seven hundred seventy one

S.No.	Financial Year	Name of Faculty (Principal Investigator)	Name of the Funding agency	Title of the Project	Sanctioned order no.	Sanctioned date	Amount Received (In Rupees)	Amount received (in words)
		5. Dr B S Kodkany Dr. M.C Metgud	1. The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA 2. Norwegian Agency for Development Cooperation (NORAD), Oslo, Norway 3. Laerdal Foundation, Stavanger, Norway	Evaluation of HELPING BABIES BREATHE in Belgaum, Kenya and Nagpur: Does Implementation of HELPING BABIES BREATHE Save Lives?	1U10HD076457-1	06-05-2013	1,45,71,888/-	One crore forty five lakh seventy one thousand eight hundred eighty eight
		6. Dr B S Kodkany	The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA	Maternal and Newborn Health Registry (MNH Registry)	1U10HD076457-01	06-05-2013	1,09,82,201/-	One crore nine lakh eighty two thousand two hundred one

S.No.	Financial Year	Name of Faculty (Principal Investigator)	Name of the Funding agency	Title of the Project	Sanctioned order no.	Sanctioned date	Amount Received (In Rupees)	Amount received (in words)
		7. Dr B S Kodkany	Bill & Melinda Gates Foundation, USA	BetterBirth Trial WHO Safe Childbirth Checklist Programm at UttarPradesh	OPP1017378	2012	9,08,001/-	Nine lakh eight thousand and one
		8. Dr B S Kodkany	1. The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA 2. Bill & Melinda Gates Foundation, USA	Preconception Maternal Nutrition: A randomized trial of the Global Network for Women's and Children's Health Research in Collaboration with the Bill and Melinda Gates Foundation"	OPP1055867	20-12-2012	1,00,35,550/-	One crore thirty five thousand five hundred fifty
		9. Dr M B Bellad	University of British Columbia, Canada Bill and Melinda Gates Foundation, USA	The CLIP (Community Level Interventions for Pre-Eclampsia) Cluster Randomized Trial	F13-03649	Sep 21, 2013	47,96,066/-	Forty seven lakh ninety six thousand sixty six
		10. Dr M B Bellad	Thrasher Research Fund, USA	Clindamycin to Reduce Preterm Birth in a Low Resource Setting: A Randomized Placebo-Controlled Trial	601465	June 22, 2013	51,65,072/-	Fifty one lakh sixty five thousand and seventy two



S.No.	Financial Year	Name of Faculty (Principal Investigator)	Name of the Funding agency	Title of the Project	Sanctioned order no.	Sanctioned date	Amount Received (In Rupees)	Amount received (in words)
		11. Dept. of Community Medicine	ICMR	A cross sectional study to compare serum lithium and urinary lithium in patients on lithium carbonate.	3/2/2010-2/PG- Thesis-MPD-3	06/08/2010	25,000/-	Twenty five thousand
		12. Dept. of Community Medicine	Karnataka Health System Development & Reforms Project (KHSDRP) Govt. of Karnataka World Bank	Baseline survey under ROAD SAFETY & emergency health care services programme at Belagavi district	IN- KA37565429812 920K	16/09/2012	5,00,000/-	Five lakhs
		13. Dept. of Community Medicine	Directorate of Health & Family Welfare Services Govt. of Karnataka	Road traffic accident safety programme (baseline survey)	IN- KA37565429812 920K	16/09/2012	5,00,000/-	Five lakhs
		14. Dr. Nikhil Hawal	ICMR	Impact of peer education on self care in Diabetes mellitus – A randomized control trial in urban field practice area	No. 3/2/2011/PG- Thesis-MPD-18	29/3/2011	25,000/-	Twenty five thousand
		15. Dr. Rakesh Nayak	ICMR	Assessment of nutritional status of under five children residing in rural area – A cross sectional study	No. 3/2/2011/PG- Thesis-MPD-4	26/09/2011	25,000/-	Twenty five thousand
		16. Dr. Praveen G.S.	Govt. of Karnataka	Prevalence of diabetes mellitus among patients registered under RNTCP	LWSTC/HS/56/2 012-13	18/02/2013	20,000/-	Twenty thousand

S.No.	Financial Year	Name of Faculty (Principal Investigator)	Name of the Funding agency	Title of the Project	Sanctioned order no.	Sanctioned date	Amount Received (In Rupees)	Amount received (in words)
		17. Dr. Mubashir Angolkar	ICMR	Study to understand prevention and explore bottle neck for women : a multi stakeholder prospective on vaginal microbicides and other NPT	5/7/703/09-RHN	23/08/2012	9,23,024/-	Nine lakh twenty three thousand twenty four
		18. Dr. N. K. Hashilkar	SPICE	Analytical study of Jatyadi, Ghrita and JatyadiGhritaAvaritini and its own healing property an experimental study	VGST/P-10/SPICE/20/11-12/1069	March 2012	30,000/-	Thirty thousand
		19. Dr.Yogesh Kumar S.	United States Agency for International Development (USAID) & KHPT, Bangalore	SHOPS TB PROJECT	MoU with Dr.Reynold Washington, Managing Trustee, KHPT, Bangalore	1 <sup>st</sup> June 2013	66,000/-	Sixty Six thousand
		20. Dr. Shivakumar Patil	Ranbaxy	Comparative Efficacy, Safety & Tolerability of fixed dose combination of Cephalexin Extended release (375 mg) & clavulanate potassium (125 mg) tables with cephalixin extended release (375 mg) Tablets in the treatment of Uncomplicated skin & soft	R2013007	21.03.2014	1,20,000/-	One lakh twenty thousand

				tissue infections – A Randomized, Double-blind study				
		21. Dr Mubashir Angolkar	ICMR Delhi	Study to understand prevention and explore respective barriers for Women ( Superb)			11,00,000/-	Eleven lakhs
		22. Dr. M.K.Swamy	Indian Council of Medical Research, New Delhi	Evaluation of a Progesterone Vaginal Ring a New Contraceptive Option in India	BT/IN/US/02/MR/2010	23 –May 2012	67,288/-	Sixty seven thousand two hundred eighty eight
		23. Dr.Mahantesh Nagamoti	KSAPS, Bangalore	HIV Sentinel Surveillance - ongoing	KSAPS/DD (M&E) / HSS /04/2012-13	11.01.2013	16,000/-	Sixteen thousand
		24. Dr.S.V.Udapudi, Dr.M.Y.Patil Dr.Archana Uppin	Eli Lilly	Protocol Title : Protocol I4V-MC-JADX: A Randomized, Double-Blind,Placebo-Controlled,Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY30091 04) in patients with Inadequate Responses to Conventional Disease-Modifying Antirheumatic Drugs with Moderately to Severely Active Rheumatoid Arthritis.			2,00,000/-	Two lakhs

<b>Financial year</b>	<b>2015-16</b>	<b>2014-15</b>	<b>2013-14</b>
Total no. of Sponsored Projects	<b>29</b>	<b>25</b>	24
Total no. of Funding Agencies	<b>21</b>	<b>19</b>	<b>12</b>
Total Amount Received (Amount in Rupees)	<b>16,26,32,425/-</b>	<b>14,80,28,089/-</b>	<b>12,14,42,861/-</b>
Amount Received in Words	<b>Sixteen crore twenty six lakh thirty two thousand four hundred and twenty five</b>	<b>Fourteen crore eighty lakh twenty eight thousand and eighty nine</b>	<b>Twelve crore fourteen lakh forty two thousand eight hundred and sixty one</b>

## Consultancy Project Details

### Consultancy Project Details

#### Prescribed format

Consultancy Projects						
S.No.	Financial Year	Name of faculty (Chief Consultant)	Client Organization	Title of Consultancy of project	Amount received (in Rupees)	Amount received (in words)
1	2015-16	<b>Dr. Rajesh Powar,</b> <b>Dr. K.M. Keluskar,</b> <b>Dr. Kotrashetti</b>  Department of Plastic Surgery, Pediatric Surgery, Oral and Maxillofacial Surgery, Orthodontics and DentofacialOrthopaedics	Smile Train, USA	1. KLE'S Smile Train project	69,00,000/-	Sixty Nine Lakh only
		<b>Dr. B.S. Kodkany Dr. S.S. Goudar,</b> <b>Dr. N.S. Mahantshetti</b> <b>Dr. M.B. Bellad</b> <b>Dr. R.M. Bellad</b> <b>Dr. S.M. Dhaded</b> <b>Dr. YeshitaPujar</b> <b>Dr. HemaDhumale</b> <b>Dr. M.c. Metgud</b>  Dept. of Paediatrics, ObG, Physiology, Community Medicine of J.N. Medical College, Belagavi	<ul style="list-style-type: none"> <li>• NIH, USA</li> <li>• NICHD, USA</li> <li>• Global Implementation Task Force of American Academy of Pediatrics, USA</li> <li>• Bill and Melinda Gate's Foundation, USA</li> <li>• WHO,</li> <li>• Thrasher Research Fund, USA</li> <li>• International Atomic Energy Agency, Vienna</li> </ul>	<ul style="list-style-type: none"> <li>• Research on Women and child Health</li> <li>• Maternal and Newborn Health Registry (MNH Registry)Dept. of OBG &amp; Paediatrics</li> <li>• Helping babies breathe initiative Dept. of Paediatrics</li> <li>• The CLIP (Community Level Interventions for Pre-Eclampsia) Cluster randomized controlled trial</li> <li>• Dept. of OBG</li> <li>• Does Implementation of Helping Babies Breathe (HBB) save lives?</li> <li>• Dept. of Paediatrics</li> </ul>	21,88,000/-	Twenty one lakhs eighty eight thousand

			<ul style="list-style-type: none"> <li>• RHR Division of World Health Organization, Geneva, Switzerland</li> <li>• University of Colorado Health Sciences Center</li> <li>• The Children Investment Fund Foundation, USA</li> <li>• Research Triangle Institute USA</li> <li>• Engender Health, USA Maternal Health Task Force, USA</li> <li>• International Atomic Energy Agency, Vienna</li> </ul>	<ul style="list-style-type: none"> <li>• Antenatal corticosteroids trial in preterm births to increase neonatal survival in developing countries (ACT) in Belagavi District, Karnataka, India</li> <li>• Dept. of OBG &amp; Paediatrics</li> <li>• Emergency obstetrics and newborn care (EmONC Project)Dept. of Paediatrics &amp; OBG</li> <li>• Women first: Preconception maternal nutrition: A randomized trialDept. of OBG</li> <li>• Brain research to ameliorate impaired neurodevelopment: Home-based intervention trial (BRAIN HIT)Dept. of Paediatrics</li> <li>• Two community strategies comparing use of misoprostol for early treatment / secondary prevention to primary prevention for postpartum hemorrhage: a randomized cluster non-inferiority study in Vijayapura district, Karnataka, India</li> <li>• Dept. of OBG</li> <li>• Active management of the third stage of labour without controlled cord traction: A randomized non-inferiority controlled trial</li> <li>• Dept. of OBG</li> <li>• Clindamycin to reduce preterm</li> </ul>		
--	--	--	--	---	--	--

				<p>birth in low resource setting: A randomized placebo controlled trial</p> <ul style="list-style-type: none"> <li>• Dept. of OBG</li> <li>• Safe childbirth checklist – single site pilot study</li> <li>• Dept. of Paediatrics</li> <li>• HIV – Couple violence survey Dept. of OBG</li> <li>• Pilot study of an indicator to measure intrapartum stillbirth and immediate neonatal death (ISINDI)</li> <li>• Dept. of OBG</li> <li>• Zinc and iron bioavailability from bio-fortified pearl millet Dept. of Paediatrics</li> </ul>		
		<p><b>Dr. M.V, Jali</b> <b>Dr. R.S. Mudhol</b></p> <p>KLE Dr. Prabhakar Kore Hospital &amp; MRC, Belagavi</p>	Govt. of Karnataka Insurance companies	<ol style="list-style-type: none"> <li>2. Yashaswini,</li> <li>3. Balasanjivini,</li> <li>4. Arogya Bhagya,</li> <li>5. Vajapayee Arogyashree Scheme,</li> <li>6. Ex-servicemen Contributory Health Scheme (ECHS),</li> <li>7. Employee's State Insurance (ESI), DBCS</li> </ol>	6,18,91,767/-	Six crore eighteen lakh ninety one thousand seven hundred and sixty seven
<b>20<sup>th</sup> January, 2013.</b>		<p>Dr .V. A. Kothiwale - <b>PI</b> Dr.Aditya.Kulkarni-<b>Sub-I</b> Dr. M S Ganachari-<b>CRC</b> Bhupendra Parihar- <b>CRC</b> Disha Khoda- <b>CRC</b></p>	Norwich	8. Protocol title: “A proof of concept, parallel design, single treatment, double arm trial of 50 mg quick dissolve tablets containing freeze dried <i>Lactobacillus delbrueckii subsp. bulgaricus lysate</i>	40,000/-	Forty thousand

				(GenCix™) from FraXon technologies Inc., USA, conducted on treatment naïve chronic hepatitis C positive patients in one arm and treatment naïve chronic hepatitis C positive patients on dialysis in the other arm”		
	<b>20/12/2011</b>	Dr. Gajanan.S.Gaude – <b>PI</b> Dr. V.A.Kothiwale – <b>Sub-I</b>	Glenmark	9. Protocol Number: GPL-CT/20111011/III“ A Phase III, randomized, open label, Non-inferiority, active-controlled comparative, parallel group, multicentric study of fixed dose combination of formoterol 12 µg plus fluticasone 250 µg as DPI (Test Drug) with the commercially available fixed dose combination of Salmeterol 50µg and Fluticasone250 µg (Seretide™Accuhaler™ 50/250 µg) as DPI in a 12-week Treatment period of adolescent and adult subjects with moderate-severe stable persistent asthma”	40,000/-	Forty thousand
			Glenmark	10. Protocol title - C003 – “A double blind, randomized, placebo controlled, parallel group, three arm, multicenter and multinational pivotal study to assess the efficacy and safety of two dosage regimens	40,000/-	Forty thousand



				of Crofelemer tablets in the treatment of moderate to severe acute watery diarrhea in adult patients.”		
	<b>05/05/2012</b>	Dr.N.S.Mahantshetti- <b>PI</b> Dr. Joshi- <b>Sub-I</b>	Bharat Biotech	11. Protocol title -“A phase II/III randomized, single blinded, active controlled study to evaluate the immunogenicity and safety of inactivated Japanese encephalitis vaccine in healthy volunteers”.	50,000/-	Fifty thousand
	<b>16/02/2011</b>	Dr. V.D.Patil - <b>PI</b> Dr. Preeti Amarkhed- <b>Sub I</b> Dr.M S Ganachari - <b>CRC</b>	Biological E. Limited	12. Trial no: BECT/JEV-PII-III/018, Protocol no: bect018/jev-pii-iii/ctp-02 “A multicentric, open label randomized controlled phase ii/iii study to evaluate the safety and immunogenicity of be’s inactivated je vaccine in healthy $\geq 1$ to $<3$ year old Indian children”	45,000/-	Forty five thousand
			Panacea	13. Protocol number: PBL/CR/0032008/CT “A randomized, multicenter, open label, comparative study to evaluate the Immunogenicity and reactogenicity of a new fully liquidpentavalentDTwP-Hib-IPV vaccine <i>EasyfourPol</i> <sup>TM</sup> , Panacea Biotec Ltd) with tetravalent DTwP/Hib vaccine ( <i>TetrAct-Hib</i> <sup>TM</sup> ), co-administered with <i>Imovax Polio</i> <sup>®</sup> (Salk Based Inactivated Polio Vaccine) of Sanofi Pasteur India Pvt. Ltd.	40,000/-	Forty thousand

				In healthy infants.		
			Reliance	14. Protocol number :RLS/TP/2010/03:“Prospective, multicentric, open label, clinical study to evaluate efficacy and safety of R-TPR-004 in patients undergoing treatment for acute ischemic stroke”	25,000/-	Twenty five thousand
			Quintile	15. Protocol number: DU176b-C-U305: “A phase 3, randomized, double-blind, double-dummy, parallel-group, multi-center, multinational study for the evaluation of efficacy and safety of (lmw) heparin/edoxaban versus (LMW) Heparin/Warfarin in subjects with symptomatic deep-vein thrombosis and/or pulmonary embolism”	30,000/-	Thirty thousand
			George Institute	16. Protocol number BC22140 ALEGLITAZAR (RO0728804): “Phase 3 multicenter, randomized, double-blind, parallel group, placebo controlled study cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ASC) event and type 2 diabetes mellitus (T2D)”	20,000/-	Twenty thousand

	20/01/2010	Dr. M. Khanpet – <b>PI</b> Dr. Vinayak Ekbot – <b>Sub I</b> Dr. M S Ganachari - <b>CRC</b>	Clinigene, International Ltd	17. Protocol title: “A phase II, randomized, open label, single subcutaneous dose study of polysialylated erythropoietin to assess safety, pharmacodynamic & pharmacokinetics in chronic kidney disease patients not on dialysis.”	30,000/-	Thirty thousand
			Quintile	18. Protocol number: DU176b-C-U301: “A Phase 3, randomised, double-blind, double dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of du-176b versus warfarin in subjects with atrial fibrillation-effective anticoagulation with Factor xA Next Generation in atrial fibrillation” (ENGAGE-AF TIMI – 48)	35,000/-	Thirty five thousand
			GlaxoSmithKline	19. Protocol title: “A phase III, open-label, randomized, multicenter study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (Infanrixhexa™) administered to Indian infants according to 6-10-14 weeks and a 2-4-6 months schedule”.	30,000/-	Thirty thousand
	26/06/2012	Dr .V. A. Kothiwale – <b>PI</b>	Thrombosis Research	20. Protocol number TRI08888	50,000/-	Fifty

		Dr. M. S. Ganachari - <b>CRC</b> Khoremand Bhatena- <b>CRC</b> Atul.Aggrawal- <b>CRC</b>	Institute	GARFIELD:“Prospective, multicentre, international registry of male and female patients newly diagnosed with atrial fibrillation”.		thousand
			SHAN Pharmaceuticals	21. Protocol Study Number: SH501:“Safety, immune lot-to-lot consistency and non-inferiority of Shan 5 (DTwP-HepB-Hib) vaccine in comparison to pentavac SD when administered as a single booster dose at 15-18 months and three dose at 6-8,10-12 and 14-16 weeks of age in healthy indian children and infants”	30,000/-	Thirty thousand
			Glenmark	22. Protocol number: GPL/CT/2012/III: “A randomised, double-blind, comparative, prospective, multicentre, parallel study to assess efficacy, safety and tolerability of Repaglidine/Metformin IR tablet monotherapy or repaglidine tablet monotherapy in adult patients with type 2 diabetes mellitus inadequately controlled on metformin alone”	35,000/-	Thirty five thousand
	<b>16/07/2012</b>	Dr. M.V. Jali - <b>PI</b>	ICON Clinical Research-Company	23. Protocol number: CV181169 :A multicentre, randomised, double-blind, active-controlled, parallel group, phase 3 trial to evaluate the	45,000/-	Forty five thousand

				safety of add-on therapy with Saxagliptin and Dapagliflozin added to Metformin compared to add-on therapy with Saxagliptin in combination with Metformin or Dapagliflozin in combination with Metformin in Subjects with type 2 Diabetes who have inadequate glycemic control on Metformin alone.”		
			Glenmark	24. Protocol number: GRC17536-203: “A Phase 2, 4-week randomized, double-blind, parallel group, placebo controlled proof of concept study to evaluate efficacy, safety and tolerability of grc 17536 in patients with painful diabetic peripheral neuropathy.”	30,000/-	Thirty thousand
	<b>03/10/2012</b>	Dr. M.V. Jali – <b>PI</b>	Piramal Healthcare	25. Protocol number: P2202/47/10: “A Phase II, randomized, double-blind, placebo-controlled, dose-ranging, two-staged, fixed design study to evaluate the efficacy, safety, tolerability and pharmacokinetics of p2202 in overweight/obese patients of type 2 diabetes mellitus inadequately controlled on metformin, sulphonyl urea, or both.”	50,000/-	Fifty thousand
	<b>24/01/2013</b>	Dr .V. A. Kothiwale - <b>PI</b> Dr. M S Ganachari- <b>CRC</b>	Amgen Technology Pvt.ltd	26. Protocol no: 20110118:“A double-blind, randomized,	30,000/-	Thirty thousand

		Tarang Shah - CRC		placebo-controlled, multicenter study assessing the impact of additional LDL-cholesterol reduction on major cardiovascular events when AMG 145 is used in combination with statin therapy in patients with clinically evident cardiovascular disease”.		
			Glenmark	27. Study title: “A Phase III prospective, randomized, open labelled, multicentric, parallel group, three arms clinical study to evaluate the efficacy and safety between monotherapy of Glenmark’sRoflumilast 500 Mcg Tablet and Combination Therapy of Roflumilast 500 Mcg Tablet Plus Tiotropium 9 mcg inhalation and combination therapy of roflumilast 500 mcg tablet plus salmeterol 25mcg inhalation in adult patients with chronic obstructive pulmonary disease (COPD).”	25,000/-	Twenty five thousand
			Serum Institute	28. Protocol title: “A multicentricrandomized , comparative clinical trial to assess the immunogenicity and reactogenicity of DPTw [meat free] vaccine with standard commercially available DPTw [routine] vaccine in Indian	40,000/-	Forty thousand

				children aged 6 –14 weeks”.		
			Reliance	29. Protocol title: To study the safety and efficacy of R-TPR – 001 (Reteplase- Recombinant plasminogen activator) in patients with acute myocardial infarction and ST segment elevation”.	20,000/-	Twenty thousand
			Novonordisk	30. Protocol title: EX 1000-1919: A multicentre, multinational, randomized, open labeled, two armed, parallel group trial with a 24 week treatment period comparing the efficacy and safety of two concentrations of Mixtard 30 (333IU/mL) or Mixtard 30 (1000IU/mL)”.	20,000/-	Twenty thousand
			SMO India.	31. Protocol title: A Phase III , multicenter, randomized , double – blind study to evaluate the efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes mellitus and chronic renal insufficiency who have inadequate glycemic control”	30,000/-	Thirty thousand
2	2014-15	1 Dr.Rajesh Powar	<ul style="list-style-type: none"> <li>Smile Train,USA</li> </ul>	1. KLE,S Smile Train project		Seventy One Lakh Fifty Nine Thousand only/-
		2	<ul style="list-style-type: none"> <li>NIH, USA</li> <li>NICHD, USA</li> </ul>	2. Research on Women and child Health 3. Maternal and Newborn Health	71,59,000/- 20,82,000/-	Twenty lakhs eighty two

			<ul style="list-style-type: none"> <li>• Global Implementation Task Force of American Academy of Pediatrics, USA</li> <li>• Bill and Melinda Gate’s Foundation, USA</li> <li>• WHO,</li> <li>• Thrasher Research Fund, USA</li> <li>• International Atomic Energy Agency, Vienna</li> <li>• RHR Division of World Health Organization, Geneva, Switzerland</li> <li>• University of Colorado Health Sciences Center</li> <li>• The Children Investment Fund Foundation, USA</li> <li>• Research Triangle Institute USA</li> <li>• Engender Health, USA Maternal Health Task Force, USA</li> <li>• International Atomic Energy Agency, Vienna</li> </ul>	<p>Registry (MNH Registry)Dept. of OBG &amp; Paediatrics</p> <p>4. Helping babies breathe initiative Dept. of Paediatrics</p> <p>5. The CLIP (Community Level Interventions for Pre- Eclampsia) Cluster randomized controlled trialDept. of OBG</p> <p>6. Does Implementation of Helping Babies Breathe (HBB) save lives?Dept. of Paediatrics</p> <p>7. Antenatal corticosteroids trial in preterm births to increase neonatal survival in developing countries (ACT) in Belagavi District, Karnataka, IndiaDept. of OBG &amp; Paediatrics</p> <p>8. Emergency obstetrics and newborn care (EmONC Project) Dept. of Paediatrics &amp; OBG</p> <p>9. Women first: Preconception maternal nutrition: A randomized trial Dept. of OBG</p> <p>10. Brain research to ameliorate impaired neurodevelopment: Home-based intervention trial (BRAIN HIT) Dept. of Paediatrics</p> <p>11. Two community strategies comparing use of misoprostol for early treatment / secondary prevention to primary</p>	thousand
--	--	--	---	---	----------



			<p>prevention for postpartum hemorrhage: a randomized cluster non-inferiority study in Vijayapura district, Karnataka, India Dept. of OBG</p> <p>12. Active management of the third stage of labour without controlled cord traction: A randomized non-inferiority controlled trial Dept. of OBG</p> <p>13. Clindamycin to reduce preterm birth in low resource setting: A randomized placebo controlled trial Dept. of OBG</p> <p>14. Safe childbirth checklist – single site pilot study Dept. of Paediatrics</p> <p>15. HIV – Couple violence survey Dept. of OBG</p> <p>16. Pilot study of an indicator to measure intrapartum stillbirth and immediate neonatal death (ISINDI) Dept. of OBG</p> <p>17. Zinc and iron bioavailability from bio-fortified pearl millet Dept. of Paediatrics</p>		
3	15. Govt. of Karnataka Insurance companies	<ul style="list-style-type: none"> <li>• Yashaswini,</li> <li>• Balasanjivini,</li> <li>• Arogya Bhagya,</li> <li>• Vajapayee Arogyashree Scheme,</li> <li>• Ex-servicemen Contributory Health Scheme (ECHS),</li> <li>• Employee's State Insurance</li> </ul>	5,09,72,744/-	Five crore nine lakh seventy two thousand seven hundred and forty	

				(ESI), DBCS		four
	<b>30/06/2014</b>	<b>Dr.(Mrs)N.S.Mahantshetti - PI</b>	18. Biological E. Limited – Company	18. Protocol title: A Multicentric double blind single arm randomized phase IV study to evaluate the safety, reactogenicity and lot consistency of three production lots of BE's combined liquid Pentavalent DTwP-rHepB-HIB vaccine administered at 6-10-14 weeks schedule to 6-8 week old healthy Indian infants.	75,000/-	Seventy thousand
			19. SMO India – CRO	19. Protocol no: GLP114130: “A randomized, double-blind, active-controlled, parallel group, multicenter study to determine the efficacy and safety of Albiglutide as compared with Sitagliptin in subjects with type 2 Diabetes mellitus with renal impairment”	80,000/-	Eighty thousand
			20. Abbott	20 Protocol title: A prospective multicenter observational study to characterize the patient population with cholestasis in chronic liver disease due to non-alcoholic liver disease receiving heptal in India[P13-163]	70,000/-	Seventy thousand
			21. Panacea Biotec Ltd	21.Protocol number: PBL/CR/0032008/CT “A randomized, multicenter, open label, comparative study to	1,00,000/-	One lakh

				evaluate the immunogenicity and reactogenicity of a new fully liquid Pentavalent DTwP-Hib-IPV vaccine ( <i>easyfourPol™</i> ) with tetravalent DTwP/Hib vaccine ( <i>TetrAct-Hib™</i> ), co-administered with <i>Imovax Polio®</i> ( <i>Salk Based Inactivated Polio Vaccine</i> ) of Sanofi Pasteur India Pvt. Ltd. In Healthy Infants.		
			22. ICON	22. Protocol no: MB102073: “A multicenter, randomized, double-blind, placebo-controlled, parallel group, phase iii trial to evaluate the safety and efficacy of dapagliflozin in subjects with type 2 Diabetes with inadequately controlled Hypertension on an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker”.	50,000/-	Fifty thousand
				23. Protocol no: MB102077: “A multicentre, randomized, double-blind, placebo-controlled, parallel group, phase III trial to evaluate the safety and efficacy of Dapagliflozin in subjects with type @ Diabetes with inadequately controlled hypertension treated with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) and an additional antihypertensive medication”.	40,000/-	Forty thousand
			42. Clinigene	24. Protocol number: MK-0822:	50,000/-	Fifty

			International Ltd	“Phase III randomized, placebo – controlled clinical trial to assess the safety and efficacy of Odanacatib (mk-0822) to reduce the risk of fracture in osteoporotic post menopausal women treated with vitamin D and calcium”.		thousand
	<b>16/02/2011</b>	Dr. V.D.Patil - <b>PI</b> Dr. Preeti Amarkhed- <b>Sub I</b> Dr.M S Ganachari – <b>CRC</b>	45. Biological E. Limited - Company	25. Trial no: BECT/JEV-PII-III/018, Protocol no: bect018/jev-pii-iii/ctp-02 “A multicentric, open label randomized controlled phase II/III study to evaluate the safety and immunogenicity of be’s inactivated JE vaccine in healthy $\geq 1$ to $<3$ year old Indian children”	70,000/-	Seventy thousand
<b>3</b>	<b>2013-14</b>	<b>1.</b> <b>Dr.Rajesh. Power</b>	<ul style="list-style-type: none"> <li>Smile train USA</li> </ul>	1. KLE’S Smile Train project	69,12,000/-	Sixty Nine Lakh Twelve thousand Only
		2	<ul style="list-style-type: none"> <li>NIH, USA</li> <li>NICHD, USA</li> <li>Global Implementation Task Force of American Academy of Pediatrics, USA</li> <li>Bill and Melinda Gate’s Foundation, USA</li> <li>WHO,</li> <li>Thrasher Research Fund, USA</li> <li>International Atomic</li> </ul>	<ul style="list-style-type: none"> <li>Research on Women and Child Health</li> <li>Maternal and Newborn Health Registry (MNH Registry) Dept. of OBG &amp; Paediatrics</li> <li>Helping babies breathe initiative Dept. of Paediatrics</li> <li>The CLIP (Community Level Interventions for Pre- Eclampsia) Cluster randomized controlled trial Dept. of OBG</li> </ul>	20,58,000/-	Twenty lakhs fifty eight thousand

			<p>Energy Agency, Vienna</p> <ul style="list-style-type: none"> <li>• RHR Division of World Health Organization, Geneva, Switzerland</li> <li>• University of Colorado Health Sciences Center</li> <li>• The Children Investment Fund Foundation, USA</li> <li>• Research Triangle Institute USA</li> <li>• Engender Health, USAMaternal Health Task Force, USA</li> <li>• International Atomic Energy Agency, Vienna</li> </ul>	<ul style="list-style-type: none"> <li>• Does Implementation of Helping Babies Breathe (HBB) save lives? Dept. of Paediatrics</li> <li>• Antenatal corticosteroids trial in preterm births to increase neonatal survival in developing countries (ACT) in Belagavi District, Karnataka, India Dept. of OBG &amp; Paediatrics</li> <li>• Emergency obstetrics and newborn care (EmONC Project) Dept. of Paediatrics &amp; OBG</li> <li>• Women first: Preconception maternal nutrition: A randomized trial Dept. of OBG</li> <li>• Brain research to ameliorate impaired neurodevelopment: Home-based intervention trial (BRAIN HIT) Dept. of Paediatrics</li> <li>• Two community strategies comparing use of misoprostol for early treatment / secondary prevention to primary prevention for postpartum hemorrhage: a randomized cluster non-inferiority study in Vijayapura district, Karnataka, India</li> </ul>		
--	--	--	--	--	--	--

				Dept. of OBG		
			Govt. of Karnataka Insurance companies	<ul style="list-style-type: none"> <li>• Yashaswini,</li> <li>• Balasanjivini,</li> <li>• Arogya Bhagya,</li> <li>• Vajapayee Arogyashree Scheme,</li> <li>• Ex-servicemen Contributory Health Scheme (ECHS),</li> <li>• Employee's State Insurance (ESI), DBCS</li> <li>• Psychiatry Day Care Center</li> </ul> KLE Dr. Prabhakar Kore Hospital & MRC Belagavi	3,54,51,688/-	Three crore fifty four lakh fifty one thousand six hundred and eighty eight
	<b>16/07/2012</b>	Dr. M.V. Jali – <b>PI</b>	ICON Clinical Research-Company	2. Protocol no: CV181169 : “A multicentre, randomised, double-blind, active-controlled, parallel group, phase 3 trial to evaluate the safety of add-on therapy with saxagliptin and dapagliflozin added to metformin compared to add-on therapy with saxagliptin in combination with Metformin or Dapagliflozin in combination with	29,97,000/-	Twenty nine lakhs ninety thousand

				Metformin in subjects with Type 2 Diabetes who have inadequate glycemic control on metformin alone”.		
			Glenmark - Company	3. Protocol title - C003 - a double blind, randomized, placebo controlled, parallel group, three arm, multicenter and multinational pivotal study to assess the efficacy and safety of two dosage regimens of crofelemer tablets in the treatment of moderate to severe acute watery diarrhea in adult patients.	70,000/-	Seventy thousand
			ZYDUS	4. Protocol no:CLR_10_22 :“Efficacy and safety of SPIL’s Lubriprostone capsule, 24 mcg Lubriprostone in subjects with chronic idiopathic constipation :a randomized, double blind, parallel group, active and placebo controlled, clinical endpoint bioequivalence study ”.	50,000/-	Fifty thousand

	<b>29/07/2013</b>	<b>Dr. Jayaprakash Appajigol-PI</b>	SUN PHARMA	5. Protocol no: ZYH 1.12.001.01 PROT: “A multicenter, prospective, randomized, open label phase IV clinical study to evaluate the safety and efficacy of saroglitazar (ZYH1) as compared to fenofibrate in patients with dyslipidemia”.	50,000/-	Fifty thousand
	<b>17/09/2013</b>	<b>Dr. M.V. Jali –PI</b>	ELI LILLY	6. Protocol title: “A demonstration project to evaluate the effectiveness and acceptability of the joint diabetes evaluation (JADE) & diabetes monitoring database(Diamond) programs in Type 2 Diabetes patients in India”.	50,000/-	Fifty thousand
			ELI LILLY	7. Protocol title: Protocol I4V-MC-JADX: A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of baricitinib (LY3009104) in patients with inadequate response to conventional disease-modifying antirheumatic drugs with moderately to severely active rheumatoid arthritis.	60,000/-	Sixty thousand



			ELI LILLY	8. Protocol title: Protocol I4V-MC-JADZ- “A randomized, double-blind, active-controlled, phase 3 study to evaluate the efficacy and safety of baricitinib (LY3009104) in patients with moderately to severely active rheumatoid arthritis who have had limited or no treatment with disease modifying antirheumatic drugs”.	45,000/-	Forty five thousand
	<b>07/11/2013</b>	<b>Dr. Udapudi-PI</b>				
			ELI LILLY	9. Protocol title: I4V-MC-JADY(C): “A Phase 3, multicenter study to evaluate the long-term safety and efficacy of baricitinib in patients with rheumatoid arthritis”.	40,000/-	Forty Thousand
	<b>17/10/2014</b>	<b>Dr.S.Udapudi-PI</b>				
			ELI LILLY	10. Protocol SB2-G31-RA: “A randomized, double-blind, parallel group, multicentre clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SB2 compared to remicade® in subjects with moderate to severe rheumatoid arthritis despite methotrexate therapy”.	60,000/-	Sixty thousand
	<b>07/11/2013</b>	<b>Dr.Rajendra.Bhandankar-PI</b> Dr. Sudheer Yadwad- <b>Sub I</b>				
			ELI LILLY	<b>11. Protocol I4L-MC-ABEL:</b>	50,000/-	Fifty

				<p>“A prospective, randomized, open-label comparison of a long acting basal insulin analog, LY2963016, to lantus® in combination with mealtime insulin lispro in adult patients with type 1 diabetes mellitus: the element 3 study”.</p>		thousand
			BBIL	<p>12. Protocol title: “Addendum to typhoid Vi polysaccharidetetanus toxoid protein conjugate phase III clinical trial protocol entitled:A phase III, Randomized,multicentre ,controlled study to evaluate the immunogenicity and safety of BBIL’s typhoid Vi capsular polysaccharide –tetanus toxoid protein conjugate vaccine (Typbar TCV) Vs. Referencevaccine (typbar) in healthy subjects.”.</p>	40,000/-	Forty thousand
			ZYDUS	<p>13. Reference protocol no: CLR_13_14:Study Title: “Pharmacodynamic efficacy and safety of Leuprolide depot 7.5 mg (SPIL) in subjects with</p>	50,000/-	Fifty thousand

				Prostatic Adenocarcinoma”.		
			BBIL	14. Protocol No: BBIL/JEV/IV/2012A: “A Phase IV Single dose, Open labeled, Comparative, Randomized Controlled study to evaluate the Immunogenicity and Safety of BBIL’s JENVAC(Inactivated JE vaccine)Vvs. Chinese SA-14-14-2(Live JE vaccine)vaccine in healthy volunteers”.	40,000/-	Forty thousand
			Ranbaxy	15. Ref: Protocol : “Comparative efficacy, safety and tolerability of FDC of cephalexin extended release (375mg) and Clavulanate Potassium (125 mg) tablets with Cephalexin extended release (375 mg) tablets in the treatment of uncomplicated skin and soft tissue infection - a randomized, double-blind study(study number: r2013006)”.	60,000/-	Sixty thousand
			Ranbaxy	16. Ref: Protocol : “Comparative efficacy, safety and tolerability of FDC of Cephalexin	30,000/-	Thirty thousand

				extended release (375mg) and Clavulanate Potassium (125 mg) tablets with cephalexin extended release (375 mg) tablets in the treatment of upper respiratory tract infections - a randomized, double-blind study (study number: r2013006)".		
	<b>17/03/2016</b>	<b>Dr.Jayprakash Appajigol – PI</b>	Asahi Kasei Pharma America Company	17. Ref:3-001 A randomized double-blind, placebo-controlled, Phase-3 study to assess the safety and efficacy of ART-123 in subject with severe sepsis and coagulopathy.	30,000/-	Thirty thousand
	<b>15/04/2014</b>	<b>Dr.Rajendra.Bhandankar-PI</b>	Sristek Company	18. Protocol title: “A multicenter, double-blind, vehicle controlled, parallel-group study comparing a generic Diclofenac Sodium topical gel, 1% in the treatment of subjects with osteoarthritis of the knee”.	30,000/-	Thirty thousand
			BBIL	19. Protocol no.: BBIL/ROTA/IV/2013: “Phase IV, multicenter, randomized, single-blind, study to evaluate the immunogenicity, reactogenicity& safety of the live attenuated rotavirus vaccine	45,000/-	Forty five thousand

				ROTAVAC <sup>®</sup> as a 3 dose series when administered simultaneously with or without the buffering agent following in healthy infants”.		
			Merc Company	20. Protocol title: MK-0822-083-00: “An observational follow-up study for: a phase III randomized, placebo-controlled clinical trial to assess the safety and efficacy of Odanacatib (MK-0822) to reduce the risk of fracture in osteoporotic postmenopausal women treated with vitamin D and calcium (protocol 018)”.	60,000/-	Sixty thousand
			Himalaya Drug Company, Bengaluru	21. “A comparative clinical study to evaluate the efficacy and safety of two cystone formulations in patients suffering from urolithiasis”.	30,000/-	Thirty thousand
			Progene Research Laboratories, Belagavi	22. “A Randomized, controlled, double blind study to evaluate the efficacy and safety of capsule progen in improving parameters of semen analysis in cases of male infertility due to defect in seminal parameters’.	30,000/-	Thirty thousand

--	--	--	--	--	--	--

<b>Financial year</b>	<b>2015-16</b>	<b>2014-15</b>	<b>2013-14</b>
Total no. of Consultancy Projects	<b>31</b>	<b>25</b>	<b>22</b>
Total no. of Client Organizations	<b>20</b>	<b>18</b>	<b>15</b>
Total Amount Received (Amount in Rupees)	7,18,09,767/-	6,07,49,279/-	4,83,39,488/-
Amount Received in Words	Seven crore eighteen lakh nine thousand seven hundred and sixty seven	Six crore seven lakh forty nine thousand two hundred and seventy nine	Four crore eighty three lakh thirty nine thousand four hundred and eighty eight

## Executive Development Programs

Executive Development Programs (Minimum one year duration)

### Prescribed format

Full time Executive Programs of one year duration						
S.No.	Academic Year	Name of the program	Duration	No. of Students	Amount Received (In Rupees)	Amount received (in words)
1	2015-16	Fellowship in Maternal Fetal Medicine	1 Year	01	36,000/-	Thirty six thousand
		Fellowship in Neonatology	1 Year	01	36,000/-	Thirty six thousand
		Fellowship in Non-Invasive cardiology	1 Year	01	36,000/-	Thirty six thousand
		Fellowship in Paediatric Urology	1 Year	04	1,44,000/-	One lakh forty four thousand
		Fellowship in Micro Ear Surgery	1 Year	02	72,000/-	Seventy two thousand
		Fellowship in Medical Education	1 Year	50	6,25,000/-	Six lakh twenty five thousand
2	2014-15	Fellowship in	1 Year	01	36,000/-	Thirty six thousand

S.No.	Academic Year	Name of the program	Duration	No. of Students	Amount Received (In Rupees)	Amount received (in words)
3	2013-14	Neonatology				
		Fellowship in Paediatric Urology	1 Year	02	72,000/-	Seventy two thousand
		Fellowship in Micro Ear Surgery	1 Year	01	36,000/-	Thirty six thousand
		Fellowship in Cleft & Craniofacial Surgery	1 Year	01	36,000/-	Thirty six thousand
		Fellowship in Maternal Fetal Medicine	1 Year	01	36,000/-	Thirty six thousand
		Fellowship in Non-Invasive cardiology	1 Year	04	12,24,000/-	Twelve lakh twenty four thousand
		Fellowship in Neonatology	1 Year	02	72,000/-	Seventy two thousand
PG Diploma in Public Relation	1 Year	07	1,82,000/-	One lakh eighty two thousand		

Financial year	2015-16	2014-15	2013-14
Total no. of Executive Development Programs	06	02	08
Total no. of Participants	59	51	18
Total Annual Earnings (Amount in Rupees)	9,49,000/-	5,36,000/-	16,58,000/-
Total Annual Earnings in Words	Nine lakh and forty	Five lakh and thirty six	Sixteen lakh fifty eight



	nine thousand	thousand	thousand
--	---------------	----------	----------